The partnership has pledged a total of up to $125 million in seed funding to speed-up the response to the COVID-19 virus. Currently, there are no broad-spectrum antivirals or immunotherapies for use on COVID-19.
The COVID-19 Therapeutics Accelerator will speed the process of evaluating new and repurposed treatments for COVID-19 in the immediate term, as well as other viral pathogens in the longer-term.
The Mastercard Impact Fund committed up to $25 million to catalyze the initial work of the Accelerator, which will work with the World Health Organization, government and private sector funders and organizations, as well as global regulatory and policy-setting institutions. This will allow sharing of research, coordinating investments, and pooling resources from the drug development stage through manufacturing and scale-up.
- Marsha Gordon